Deals: Page 85
-
FDA approves another antibacterial drug for skin infections
This is the third drug approved this year for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) -- and the first single, once-daily, FDA-approved antibiotic.
By Nicole Gray • Aug. 8, 2014 -
Walgreens to buck tax-inversion trend, remain in Chicago after merger
America's largest drug chain has no intention of moving abroad after merging with UK-based Alliance Boots.
By Sy Mukherjee • Aug. 6, 2014 -
FDA
Roche to buy Santaris, add gene-silencing research to its portfolio
The purchase of Denmark-based Santaris will add an important new platform to Roche’s portfolio -- the locked nucleic acid (LNA) platform.
By Nicole Gray • Aug. 6, 2014 -
Analysts: Pfizer may have its sights set on GSK
If Pfizer and GSK merged, the resulting company would hold the largest vaccine portfolio in the pharmaceutical industry.
By Nicole Gray • Aug. 5, 2014 -
EU broadens target population for life-saving cystic fibrosis drug
Based on new data, Kalydeco (ivacaftar) can now be used to treat 250 additional patients in Europe.
By Nicole Gray • Aug. 5, 2014 -
BMS and Allied Minds team up to turn academic research into a clinical reality
This venture will ultimately involve university researchers, the BMS team and experienced finance managers from Allied Minds.
By Nicole Gray • Aug. 5, 2014 -
Allergan files federal lawsuit against Valeant, Pershing Square
Allergan is accusing Valeant and Pershing Square of federal securities law violations, including insider trading and failing to disclose legally required information.
By Sy Mukherjee • Aug. 1, 2014 -
NICE gives Celgene's myeloma treatment the cold shoulder
The agency had previously approved use of Revlamid (lenalidomide) when Celgene had a patient access scheme in place.
By Nicole Gray • July 31, 2014 -
AZ buys rights to Almirall's respiratory portfolio in $2.1 billion deal
This deal signals AstraZeneca’s strength and independence.
By Nicole Gray • July 31, 2014 -
Can GSK overcome its Q2 blues by focusing on the future?
In the face of corruption allegations and diminished earnings forecasts, GSK is looking toward the horizon.
By Nicole Gray • July 29, 2014 -
Roche developing diagnostic test to support AZ's lung cancer candidate
Another example of how personalized medicine is improving cancer therapeutics.
By Nicole Gray • July 29, 2014 -
Boehringer and Zealand Pharma team up again to tackle obesity, diabetes
This is the second collaborative agreement between the two companies.
By Nicole Gray • July 29, 2014 -
Analysts on AbbVie's Shire deal: billions in tax savings
GlobalData analysts say moving business operations to Ireland will lower AbbVie’s taxes by 7%.
By Nicole Gray • July 29, 2014 -
Onco360 to distribute Gilead's Zydelig
PharMerica Corporation owns a substantial portion of Onco360.
By Nicole Gray • July 28, 2014 -
Reckitt Benckiser to spin off pharmaceutical business
RB Pharmaceuticals will become a stand-alone business, with the core company focusing on consumer health and hygiene.
By Nicole Gray • July 28, 2014 -
President Obama slams tax-inversion mergers: 'An unpatriotic tax loophole'
"We need to stop companies from renouncing their citizenship just to get out of paying their fair share of taxes," the president said Thursday.
By Sy Mukherjee • July 24, 2014 -
Lannett inks exclusive deal to distribute ACEON generic in the U.S.
Lannett will be the exclusive American distributor for a generic version of Symplmed Pharmaceuticals' hypertension drug ACEON.
By Nicole Gray • July 22, 2014 -
Major Allergan shareholder dumps stock in vote of no confidence
Capital Research and Management Co. is shedding almost all of its holdings in Botox-maker Allergan.
By Nicole Gray • July 22, 2014 -
AbbVie, Shire agree to $54.6 billion merger to slash corporate tax rate
This long-awaited cash-and-stock deal is a tax-inversion merger.
By Nicole Gray • July 18, 2014 -
Lilly, Immunocore partner to develop immunotherapy-based cancer treatments
Immunocore will receive up to $25 million for each candidate that is discovered and accepted by Lilly for clinical development.
By Nicole Gray • July 17, 2014 -
Dicerna Pharmaceuticals moving to Cambridge, MA
The company, which had the largest biotech IPO in MA so far this year, is doubling its footprint and moving into a former Pfizer space.
By Nicole Gray • July 17, 2014 -
Pfizer brings InnoPharma into the fold
The deal is worth up to $360 million and brings a strong portfolio of approved drugs and an even stronger pipeline.
By Nicole Gray • July 17, 2014 -
Oncology CROs merging to offer broader range of services
The goal of the merger between Chiltern and Ockham is to become the “premier specialized mid-tier CRO" for oncology services.
By Nicole Gray • July 16, 2014 -
Valeant moves forward with premerger notification to FTC, Allergan holds its own
The company is filing under the FTC’s Hart-Scott-Rodino Antitrust Improvement Act of 1976.
By Nicole Gray • July 15, 2014 -
AbbVie increases offer price for Shire
The deal is now valued at $53 billion.
By Nicole Gray • July 15, 2014
Previous
